Results 171 to 180 of about 713,346 (360)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Benzamide derivatives and their constrained analogs as histamine H 3 receptor antagonists

, 2015
Ramakrishna Nirogi, Anil Shinde, Vinaykumar Tiriveedhi, Laxman Kota, Sangram Keshari Saraf, Rajesh Kumar Badange, Abdul Rasheed Mohammed, Ramkumar Subramanian, Nageshwararao Muddana, Gopinadh Bhyrapuneni, Renny Abraham   +10 more
openalex   +1 more source

Phenylalanine-Based AMPA Receptor Antagonist as the Anticonvulsant Agent with Neuroprotective Activity—In Vitro and In Vivo Studies [PDF]

, 2022
Gniewomir Latacz, Kinga Sałat, Anna Furgała, Adrian Martyniak, Agnieszka Olejarz‐Maciej, Ewelina Honkisz-Orzechowska, Ewa Szymańska   +6 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Lemborexant, a Dual Orexin Receptor Antagonist, ameliorates Tau‐mediated Sleep Loss and Neurodegeneration [PDF]

Samira Parhizkar, Wei Chen, Xin Bao, Grace Gent, Nicholas Rensing, Eric Tycksen, Emily Franke, Melissa Manis, Megan E. Bosch, Choonghee Lee, Javier Remolina Serrano, Eric C. Landsness, Michael Wong, David M. Holtzman   +13 more
openalex   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Characterization of angiotensin II antagonism displayed by KR-31081, a novel nonpeptide AT1 receptor antagonist [PDF]

, 2009
Sung-Hou Lee
openalex   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

The NMDA Receptor Antagonist Memantine Modulates Aging and Stress Resilience. [PDF]

Aging Cell
Juozaityte V, Pregnolato C, Abay-Nørgaard S, Rausch DM, McIntyre RL, Gerhart-Hines Z, Pers TH, Salcini AE, Clemmensen C.   +8 more
europepmc   +1 more source

In Vitro Pharmacological Properties of KRH-594, a Novel Angiotensin II Type 1 Receptor Antagonist.

, 1997
Koichi Tamura, Masayasu Okuhira, Imao Mikoshiba, Ken Hashimoto   +3 more
openalex   +2 more sources